Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk
Austrian haematology/cardiology expert p… · 2019 · Austria
Source and licence
- Authors
- Markus C. Stühlinger, Ansgar Weltermann, Philipp Staber et al.
- Title
- Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk
- Journal
- Wiener Klinische Wochenschrift, 2019
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC7035304
Licence statement of the original publication
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
Ibrutinib is the first clinically approved inhibitor of Bruton’s tyrosine kinase, an enzyme that is essential for survival and proliferation of B‑cells by activating the B‑cell receptor signalling pathway. Ibrutinib has been shown to be highly effective in B‑cell malignancies in clinical trials and is recommended in current international guidelines as a first and/or second line treatment of chronic lymphocytic leukemia. The drug has a favorable tolerability and safety profile but the occurrence of specific side effects (e.g. atrial fibrillation, bleeding and hypertension) may complicate or be of concern for doctors and patients considering the use of this treatment. In many cases, however, it is not necessary to withhold this effective therapy. In contrast, ibrutinib treatment can be initiated or continued, if certain recommendations are followed. The possibilities of prevention, diagnosis and management of specific clinical situations are discussed in detail and recommendations are derived, which should facilitate ibrutinib use.
Contents of the original publication
The section headings of the original.
- Ibrutinib—mode of action and appropriate use
- Dosing, adjustments and severity grades of adverse events
- Special considerations in individual patients
- Atrial fibrillation
- Bleeding
- Drug-drug interactions (DDI)
- Practical guide for patients considered for or treated with ibrutinib
- Cardiovascular risk stratification before initiation of ibrutinib treatment
- Management of side effects during ibrutinib therapy
- Conclusion
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint